UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 76

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

Pituitary, 2020-04, Vol.23 (2), p.171-181

2020

Volltextzugriff (PDF)

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study

Endocrine, 2019-01, Vol.63 (1), p.120-129

2019

Volltextzugriff (PDF)

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

Endocrine, 2023-03, Vol.79 (3), p.527-536

2023

Volltextzugriff (PDF)

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

European journal of nuclear medicine and molecular imaging, 2020-09, Vol.47 (10), p.2358-2371

2020

Volltextzugriff (PDF)

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England

Drugs -- real world outcomes, 2024-06, Vol.11 (2), p.195-207

2024

Volltextzugriff (PDF)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Pituitary, 2016-04, Vol.19 (2), p.149-157

2016

Volltextzugriff (PDF)

SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study

Pituitary, 2016-02, Vol.19 (1), p.39-49

2016

Volltextzugriff (PDF)

ODP108 Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva: Methodology of the Phase III Open-Label PIVOINE Rollover Trial

Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A171-A171

2022

Volltextzugriff (PDF)

International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly

The journal of clinical endocrinology and metabolism, 2021-12, Vol.106 (12), p.3555-3568

2021

Volltextzugriff (PDF)

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

European journal of cancer (1990), 2021-11, Vol.157, p.403-414

2021

Volltextzugriff (PDF)

Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey

Journal of neuroendocrinology, 2023-06, Vol.35 (6), p.e13281-n/a

2023

Volltextzugriff (PDF)

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4530-4530

2023

Volltextzugriff (PDF)

Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours

Journal of neuroendocrinology, 2022-04, Vol.34 (4), p.e13096-n/a

2022

Volltextzugriff (PDF)

Mental perception of prostate cancer (PCa) disease in patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.67-67

2020

Volltextzugriff (PDF)

Cognitive status of prostate cancer (PCa) patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy, by age group

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.74-74

2020

Volltextzugriff (PDF)

Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database Experience

Hormone research in paediatrics, 2015-01, Vol.83 (5), p.345-357

2015

Volltextzugriff (PDF)

Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study

European journal of endocrinology, 2017-02, Vol.176 (2), p.203-212

2017

Volltextzugriff (PDF)

Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST

Clinical therapeutics, 2021-10, Vol.43 (10), p.1779-1785

2021

Volltextzugriff (PDF)

Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study

Neuroendocrinology, 2023-03, Vol.113 (3), p.332-342

2023

Volltextzugriff (PDF)

OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel

European journal of endocrinology, 2023-08, Vol.189 (2), p.281-289

2023

Volltextzugriff (PDF)

Glucose and lipid levels with lanreotide autogel 120 mg in treatment‐naïve patients with acromegaly: data from the PRIMARYS study

Clinical endocrinology (Oxford), 2017-04, Vol.86 (4), p.541-551

2017

Volltextzugriff (PDF)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

Advances in therapy, 2020-04, Vol.37 (4), p.1608-1619

2020

Volltextzugriff (PDF)

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR

Clinical therapeutics, 2018-12, Vol.40 (12), p.2006-2020.e2

2018

Volltextzugriff (PDF)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

Advances in therapy, 2023-02, Vol.40 (2), p.671-690

2023

Volltextzugriff (PDF)

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study

Pituitary, 2019-10, Vol.22 (5), p.476-487

2019

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(76)

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(36)
Science & Technology
(36)
Endocrinology & Metabolism
(23)
Humans
(22)
Male
(17)
Female
(16)
Acromegaly
(15)
Patients
(15)
Middle Aged
(14)
Endocrinology
(12)
Medicine
(12)
Medicine & Public Health
(12)
Adult
(10)
Lanreotide
(10)
Neuroendocrine Tumors
(10)
Oncology
(10)
Somatostatin - Analogs & Derivatives
(10)
Acromegaly - Drug Therapy
(8)
Aged
(8)
Quality Of Life
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study

ODP108 Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva: Methodology of the Phase III Open-Label PIVOINE Rollover Trial

International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy

Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours

Mental perception of prostate cancer (PCa) disease in patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy

Cognitive status of prostate cancer (PCa) patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy, by age group

Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database Experience

Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study

Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST

Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study

OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel

Glucose and lipid levels with lanreotide autogel 120 mg in treatment‐naïve patients with acromegaly: data from the PRIMARYS study

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study

Suchergebnisse filtern